Corporate Member Update: New Coding Guidance for Recently Approved Pfizer Oncology Product
Corporate Member Update: New Coding Guidance for Recently Approved Pfizer Oncology Product
ELREXFIO (elranatamab-bccm) injection
April, 2024
Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
J1323- Injection, elranatamab-bcmm, 1 mg
We are respectfully requesting that you update your membership about this important coding change for ELREXFIO (elranatamab-bccm).
Please see full prescribing information including Boxed Warning, HERE.
